Trasylol (aprotinin) is an injectable prescription drug which acts to decrease the risk of bleeding during surgery. On November 5, 2007, the FDA announced that Bayer Pharmaceuticals Corp. agreed to a marketing suspension of Trasylol, pending detailed review of preliminary results from a Canadian study that suggested Trasylol use increased risk for death and may increase the risk for clot formation within coronary artery bypass grafts.
